Physician profile
Minerva Perez
NPI 1497261895
$13,669.43
in general payments reported to CMS, 2019-2025
34 companies · $2,933 in 2025
The $2,933 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,318 · 2022: $2,272 · 2023: $3,528 · 2024: $3,619 · 2025: $2,933.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,079.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,480.78 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,937.09 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $1,603.63 | 2022-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Gilead Sciences, INC. | $760.37 | 2022-2025 | Descovy, Epclusa, Veklury |
| Janssen Pharmaceuticals, INC | $726.51 | 2023-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $625.08 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $573.53 | 2022-2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $535.01 | 2021-2025 | Jardiance |
| Lilly USA, LLC | $445.63 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Alnylam Pharmaceuticals INC. | $374.99 | 2022-2025 | Onpattro, Amvuttra |
| Pfizer INC. | $362.33 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $321.05 | 2021-2023 | |
| Alkermes, INC. | $303.14 | 2022-2024 | Aristada, Lybalvi |
| Novo Nordisk INC | $257.85 | 2021-2025 | Rybelsus, Ozempic |
| Shionogi INC | $249.98 | 2023-2024 | Fetroja |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Melinta Therapeutics, LLC | $249.98 | 2023-2025 | Rezzayo |
| Amgen INC. | $215.45 | 2023-2024 | Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $191.34 | 2021-2025 | Xifaxan |
| Nestle Healthcare Nutrition INC. | $176.19 | 2021-2022 | |
| Dexcom, INC. | $167.21 | 2023-2025 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Exact Sciences Corporation | $154.83 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Aimmune Therapeutics, INC. | $147.46 | 2024-2025 | Zenpep |
| Novartis Pharmaceuticals Corporation | $136.14 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2022 | |
| Janssen Biotech, INC. | $124.99 | 2023 | Imbruvica |
| Octapharma USA, INC. | $122.41 | 2023 | Octagam Immune Globulin (Human) |
| Csl Behring | $95.76 | 2023 | Hemgenix |
| Biohaven Pharmaceutical Holding Company LTD. | $51.62 | 2022 | |
| Abbott Laboratories | $38.76 | 2023-2024 | Freestyle Libre 3, Freestyle Libre |
| Collegium Pharmaceutical, INC. | $38.60 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $22.62 | 2022 | |
| Horizon Therapeutics Plc | $21.86 | 2022 | |
| Linus Health, INC. | $19.40 | 2022 | |
| Paratek Pharmaceuticals, INC. | $12.84 | 2023 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Minerva Perez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.